The Effect of Dihydrosomatostatin in Dwarfism with High Plasma Immunoreactive Growth Hormone

Publisher Website
Google Scholar
Abstract
The range of the growth hormone basal level in the 5 tests on the dwarfs was 3.5-87.0 ng/ml; the basal level of the acromegalic patient was 40.5 ng/ml. SRIF [somatostatin] suppressed the IR-hGH [immunoreactive growth hormone] in the dwarfs. The range of the insulin basal level in 4 tests of the dwarf patients was 10.0-13.6 .mu.U[microunits]/ml. SRIF induced a similar suppression of insulin in both kind of patients. The rise in plasma insulin following discontinuation of the SRIF in the dwarf was variable and of lower intensity than in the acromegalic patient. The basal glucagon levels in the 3 dwarfs patients tested were 146, 105 and 157 pg/ml; in the acromegalic patient it was 108 pg/ml. The glucagon was suppressed in all the subjects tested. In the dwarf patients it returned to the initial level soon after stopping the SRIF while in the acromegalic patient there was a more prolonged suppression. In none of the subjects tested was there an effect of SRIF on the blood sugar.

This publication has 1 reference indexed in Scilit: